全國服務咨詢熱線：
18860915427
18860915427
產品分類
Product Category詳細介紹
| 品牌 | absin | CAS | 935888-69-0 |
|---|---|---|---|
| 分子式 | C25H32N4O7S | 純度 | ＞98% |
| 分子量 | 532.61 | 貨號 | abs810429 |
| 規格 | 5mg | 供貨周期 | 現貨 |
| 主要用途 | selectively inhibits CT-L activity of 20 | 應用領域 | 化工,生物產業,農林牧漁,制藥/生物制藥,綜合 |
ONX-0912(Oprozomib) 935888-69-0
| 產品描述 | |
| 描述 | Oprozomib (ONX 0912) selectively inhibits CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. |
| 純度 | >98% |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | Oprozomib;ONX-0912; ONX0912; ONX 0912; PR-047; PR047; PR 047 |
| 外觀 | 白色至類白色粉末 |
| 可溶性/溶解性 | DMSO : 93 mg/mL (174.6 mM) |
| 生物活性 | |
| 靶點 | 20S proteasome β5,20S proteasome LMP7 |
| In vitro(體外研究) | The anti-MM activity of Oprozomib is associated with activation of caspase-8, caspase-9, caspase-3, and PARP, as well as inhibition of migration of MM cells and angiogenesis. |
| In vivo(體內研究) | Oprozomib is demonstrated an absolute bioavailability of up to 39% in rodents and dogs. It is well tolerated with repeated oral administration at doses resulting in >80% proteasome inhibition in most tissues and elicited an antitumor response in multiple human tumor xenograft and mouse syngeneic models . |
| 研究領域 | |
| 研究領域 | Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產品咨詢
電話
微信掃一掃
地址：上海市浦東新區新浩路58號申江科創園18棟
郵箱：fengmj@univ-bio.com
傳真：